
Teva Pharmaceutical (TEVA) Stock Forecast & Price Target
Teva Pharmaceutical (TEVA) Analyst Ratings
Bulls say
Teva Pharmaceutical Indus is viewed positively by financial analysts due to its strong commercial execution and investments in growth, with key drugs AUSTEDO and UZEDY showing promising results and potential for market expansion. However, there are concerns about competition and potential side effects for their new drugs. The company is focused on branded therapies and has a diverse portfolio, including generics and biosimilars. Teva's net-debt/EBITDA ratio is expected to improve in the future, and their updated price target is $42.
Bears say
Teva Pharmaceutical Indus is facing significant challenges due to its heavy reliance on the generic drug market, which is highly competitive and faces pricing pressures. Additionally, the company's recent pivot towards branded drugs may not have the desired impact on growth, and could potentially strain its balance sheet. Although upcoming launches and M&A activity may provide short-term growth, long-term success may be difficult to sustain without a strong pipeline and a clear strategy for its generic business.
This aggregate rating is based on analysts' research of Teva Pharmaceutical and is not a guaranteed prediction by Public.com or investment advice.
Teva Pharmaceutical (TEVA) Analyst Forecast & Price Prediction
Start investing in Teva Pharmaceutical (TEVA)
Order type
Buy in
Order amount
Est. shares
0 shares